{"id":"etoricoxib-fixed-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:03:08.085847","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the production of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective mechanism provides anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.","oneSentence":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:47.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute pain"},{"name":"Ankylosing spondylitis"}]},"_fixedFields":["pubmed(12)"],"trialDetails":[{"nctId":"NCT07454369","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-10-24","conditions":"Healthy","enrollment":42},{"nctId":"NCT06791434","phase":"PHASE4","title":"Assessing the Benefits of Dry Needling for Low Back Pain When Combined With Regular Treatment","status":"COMPLETED","sponsor":"Dr. Vishwanath Karad MIT World Peace University","startDate":"2024-08-30","conditions":"Low Back Pain","enrollment":156},{"nctId":"NCT06863662","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-09-18","conditions":"Acute Low-back Pain, Muscle Spasm; Back Pain","enrollment":136},{"nctId":"NCT07328022","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-05-14","conditions":"Bursitis, Tendinitis, Synovitis","enrollment":89},{"nctId":"NCT06863701","phase":"PHASE3","title":"Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2025-01-27","conditions":"Gout Arthritis, Gout Attack","enrollment":72},{"nctId":"NCT06517823","phase":"PHASE3","title":"Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-04-26","conditions":"Acute Low-back Pain","enrollment":190},{"nctId":"NCT05683574","phase":"PHASE3","title":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-05-30","conditions":"Third Molar Extraction","enrollment":""},{"nctId":"NCT05533073","phase":"PHASE1","title":"Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2020-08-03","conditions":"Healthy","enrollment":42},{"nctId":"NCT04968158","phase":"PHASE3","title":"Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2021-11-29","conditions":"Acute Low Back Pain","enrollment":124},{"nctId":"NCT03117894","phase":"NA","title":"PECS-2 for Breast Surgery","status":"COMPLETED","sponsor":"Umeå University","startDate":"2017-05-23","conditions":"Breast Neoplasm Female, Regional Anesthesia, Anesthesia","enrollment":200},{"nctId":"NCT01979510","phase":"PHASE3","title":"Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11","conditions":"Low Back Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"recentPublications":[{"date":"2026 Mar 12","pmid":"41813869","title":"A Prospective, Multicenter, Single-arm, Phase IV Study to Assess the Safety and Effectiveness of a Fixed-Dose Combination of Pregabalin Prolonged Release and Etoricoxib in Patients with Chronic Low Back Pain with a Neuropathic Component.","journal":"Drugs - real world outcomes"},{"date":"2025 Jun 17","pmid":"40566072","title":"Efficacy and Safety of a Fixed-Dose Combination of Etoricoxib-Tramadol Biphasic Tablet in Moderate-to-Severe Acute Pain: A Randomized, Double-Blind, Parallel-Group, Active-Controlled Trial.","journal":"Journal of clinical medicine"},{"date":"2024 Dec","pmid":"39256291","title":"Multimodal Analgesia Approach in Acute Low Back Pain Management: A Phase III Study of a Novel Analgesic Combination of Etoricoxib/Tramadol.","journal":"Pain and therapy"},{"date":"2024 Nov","pmid":"39081241","title":"Comparative Bioavailability of a Novel Fixed-dose Combination Etoricoxib and Tramadol.","journal":"Clinical pharmacology in drug development"},{"date":"2023 Oct","pmid":"38021944","title":"The Efficacy and Safety of a Combination of Thiocolchicoside and Etoricoxib in Low Back Pain (ESCoTEL): A Randomized Active-Controlled Trial.","journal":"Cureus"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etori"],"phase":"phase_3","status":"active","brandName":"Etoricoxib fixed dose","genericName":"Etoricoxib fixed dose","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}